On October 20, 2025, Biofrontera Inc. finalized agreements to acquire U.S. rights to Ameluz® and RhodoLED® from Biofrontera AG, with a payment structure based on U.S. net sales, including a 12% earnout for sales up to $65 million and 15% for sales above that threshold. This transaction is significant as it strengthens Biofrontera's portfolio and ensures compliance with Nasdaq listing requirements, maintaining stockholders' equity over $5 million.